Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07759362
PHASE3
Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)
Sponsor: Endo USA Inc., a Keenova Therapeutics Company
View on ClinicalTrials.gov
Summary
The primary purpose of this study is to assess the efficacy, safety, and tolerability of KN3835 compared to placebo in the treatment of flexible/semi-flexible HMT.
Official title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of KN3835 vs Placebo in the Treatment of Flexible/Semi-Flexible Hammertoe
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
554
Start Date
2026-08
Completion Date
2027-12
Last Updated
2026-08-12
Healthy Volunteers
No
Interventions
BIOLOGICAL
KN3835
Participants will receive KN3835.
OTHER
Placebo
Participants will receive placebo matching to KN3835.